Personalized Cannabinoid Formulations and Experiences

A next-generation system for tailoring cannabinoid formulations to individual genotypes, providing optimal experiences through real-time biometric feedback, wearable tracking, and virtual reality simulation.

The original patent's cannabinoid formulations, while innovative, have limitations in terms of personalization and adaptability. The new inventive concept addresses these limitations by integrating genotype analysis, real-time biometric feedback, and AI-driven formulation optimization to provide a truly personalized experience.

The new inventive concept comprises a system for personalized cannabinoid formulations, including a genotype analysis module, a formulation generation module, and a dispensing module. The system can also incorporate wearable devices for tracking physiological and psychological responses, and a virtual reality platform for simulating optimal cannabinoid experiences. The formulations themselves can feature novel ratios of CBD:THC:CBG, dynamically adjusted based on real-time biometric data.

The new claims introduce a paradigm shift in cannabinoid formulation technology by incorporating genotype analysis, real-time biometric feedback, and AI-driven optimization. These innovations enable a level of personalization and adaptability not possible with traditional formulations.

Alternative embodiments may include the use of machine learning algorithms to predict optimal formulations, integration with electronic health records, or the development of specialized formulations for specific medical conditions. Variations may include the use of different cannabinoids, terpenes, or other compounds to create unique formulations.

The new inventive concept has significant commercial potential in the burgeoning cannabis industry, particularly in the areas of personalized medicine, wellness, and recreational use. Target industries may include pharmaceuticals, nutraceuticals, and cannabis dispensaries.